Login

I cannot remember my username

Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now...

In Breakthrough Technology Alert, Ray Blanco tirelessly researches these exciting new breakthrough technologies and tells you exactly what you need to do to profit from them.

60% Gains for Our 5G Play!

Ray Blanco
By Ray BlancoPosted January 12, 2021
New Update

Good news is sending our 5G plays soaring! As 5G networks deploy, the devices that operate on them require more complex and higher-fidelity communications circuits. And there’s good reason to expect the company to keep growing in 2021!

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.

LoginGet Access

Ray Blanco

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

Related Posts

More Geron-Related Analysis for ISCO and Neuralstem

Patrick Cox
By Patrick CoxPosted November 22, 2011

Last week, I wrote about some of the consequences of Geron's exit from the stem cell business. Specifically, I explained why BioTime benefits. There should be several other big winners, however, besides BioTime. Both are, not coincidentally, in our portfolio. The most important in terms of scope of its platform is International Stem Cell Corp.

TOPICS | , , , , ,

NanoViricides Shows Oral Delivery and Anavex Benefits as Field of AD Drugs Narrows

Patrick Cox
By Patrick CoxPosted August 14, 2012

I have truly astounding news from NanoViricides (OTCBB: NNVC). First, however, allow me to respond to a friend who told me recently that I should have reminded my readers that I had predicted the failure of bapineuzumab, the Alzheimer's drug candidate jointly funded by Pfizer, Johnson & Johnson and Elan. So for the record, I told you so. In fact, the reason I got this right was that I listened to Dr. Cameron Durrant, formerly a top executive for several Big Pharma companies and Anavex Life Sciences Corp. (OTCBB: AVXL). Durrant knows the inside story when it comes to AD as well as the pharmaceutical industry.